Kong Leopold, Lee David E, Kadam Rameshwar U, Liu Tong, Giang Erick, Nieusma Travis, Garces Fernando, Tzarum Netanel, Woods Virgil L, Ward Andrew B, Li Sheng, Wilson Ian A, Law Mansun
Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037.
Department of Medicine, University of California, San Diego, La Jolla, CA 92037.
Proc Natl Acad Sci U S A. 2016 Nov 8;113(45):12768-12773. doi: 10.1073/pnas.1609780113. Epub 2016 Oct 24.
Hepatitis C virus (HCV) is a major cause of liver disease, affecting over 2% of the world's population. The HCV envelope glycoproteins E1 and E2 mediate viral entry, with E2 being the main target of neutralizing antibody responses. Structural investigations of E2 have produced templates for vaccine design, including the conserved CD81 receptor-binding site (CD81bs) that is a key target of broadly neutralizing antibodies (bNAbs). Unfortunately, immunization with recombinant E2 and E1E2 rarely elicits sufficient levels of bNAbs for protection. To understand the challenges for eliciting bNAb responses against the CD81bs, we investigated the E2 CD81bs by electron microscopy (EM), hydrogen-deuterium exchange (HDX), molecular dynamics (MD), and calorimetry. By EM, we observed that HCV1, a bNAb recognizing the N-terminal region of the CD81bs, bound a soluble E2 core construct from multiple angles of approach, suggesting components of the CD81bs are flexible. HDX of multiple E2 constructs consistently indicated the entire CD81bs was flexible relative to the rest of the E2 protein, which was further confirmed by MD simulations. However, E2 has a high melting temperature of 84.8 °C, which is more akin to proteins from thermophilic organisms. Thus, recombinant E2 is a highly stable protein overall, but with an exceptionally flexible CD81bs. Such flexibility may promote induction of nonneutralizing antibodies over bNAbs to E2 CD81bs, underscoring the necessity of rigidifying this antigenic region as a target for rational vaccine design.
丙型肝炎病毒(HCV)是肝脏疾病的主要病因,影响着全球超过2%的人口。HCV包膜糖蛋白E1和E2介导病毒进入细胞,其中E2是中和抗体反应的主要靶点。对E2的结构研究为疫苗设计提供了模板,包括保守的CD81受体结合位点(CD81bs),它是广泛中和抗体(bNAbs)的关键靶点。不幸的是,用重组E2和E1E2进行免疫很少能引发足够水平的bNAbs用于保护。为了了解引发针对CD81bs的bNAb反应所面临的挑战,我们通过电子显微镜(EM)、氢氘交换(HDX)、分子动力学(MD)和量热法对E2 CD81bs进行了研究。通过EM,我们观察到一种识别CD81bs N端区域的bNAb——HCV1,能从多个接近角度结合可溶性E2核心构建体,这表明CD81bs的组成部分是灵活的。多个E2构建体的HDX一致表明,相对于E2蛋白的其余部分,整个CD81bs是灵活的,MD模拟进一步证实了这一点。然而,E2的解链温度高达84.8℃,这更类似于嗜热生物的蛋白质。因此,重组E2总体上是一种高度稳定的蛋白质,但CD81bs异常灵活。这种灵活性可能会促进针对E2 CD81bs产生非中和抗体而非bNAbs,这突出了将这个抗原区域刚性化作为合理疫苗设计靶点的必要性。